New York, NY -- (SBWIRE) -- 12/24/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Forest Oil Corporation (NYSE:FST), Vantage Drilling Company (NYSEMKT:VTG), Generex Biotechnology Corporation (OTCMKTS:GNBT), Delcath Systems, Inc (NASDAQ:DCTH)
Forest Oil Corporation (NYSE:FST) showed a volume of 2.61 million shares by the end of last trade whereas the average volume of the stock remained 3.97 million shares. The stock opened the session at $3.81 but then moved to $3.76. Forest Oil Corporation (Forest) is an independent oil and gas company engaged in the acquisition, exploration, development, and production of oil, natural gas, and natural gas liquids in North America. As of December 31, 2011, Forest's total estimated proved oil and gas reserves were approximately 1,904 billions of cubic feet equivalents. As of December 31, 2011, approximately 97% of Forest's estimated proved oil and gas reserves were in the United States. Forest's core areas consist of a portfolio of tight-gas sands, carbonates, and shale plays with multiple stacked-pay opportunities in the United States that have exposure to oil, natural gas liquids, and natural gas.
Is FST a Solid Investment at These Levels? Read This Report For Details
Vantage Drilling Company (NYSEMKT:VTG) opened the session at $1.80 and closed the session at $1.78. The stock showed a negative performance of -0.56% in previous trading session. Traded with volume of 2.21 million shares in the prior session and the average volume of the stock remained 1.01 million shares. Vantage Drilling Company (Vantage Drilling) is an international offshore drilling company focused on operating a fleet of drilling units. The Company’s primary business is to contract drilling units, related equipment and work crews primarily on a dayrate basis to drill oil and natural gas wells for its customers. The Company also provides construction supervision services for, and will operate and manage, drilling units owned by others.
Has VTG Found The Bottom And Ready To Gain Momentum? Find Out Here
Generex Biotechnology Corporation (OTCMKTS:GNBT) opened the session at $0.03 and closed the session at $0.0295. The stock showed a negative performance of -1.01% in previous trading session. Traded with volume of 1.94 million shares in the prior session and the average volume of the stock remained 1.92 million shares. The beta of the stock remained 2.13. Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. Its buccal insulin spray product, Generex Oral-lyn is in Phase III clinical trials at several sites around the world. The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device.
Why Should Investors Buy GNBT After the Recent Fall? Just Go Here and Find Out
Delcath Systems, Inc (NASDAQ:DCTH) the stock decreased -6.49% and finished the session at $0.248. Traded with volume of 1.71 million shares in the prior session and the average volume of the stock remained 1.81 million shares. The beta of the stock remained 2.08. Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers doses of chemotherapeutic agents directly to the liver.
Will DCTH Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)